Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2025)
Historic Operating Leases for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $16.5 million.
- Taysha Gene Therapies' Operating Leases fell 701.37% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 701.37%. This contributed to the annual value of $17.4 million for FY2024, which is 839.97% down from last year.
- According to the latest figures from Q3 2025, Taysha Gene Therapies' Operating Leases is $16.5 million, which was down 701.37% from $16.8 million recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Operating Leases registered a high of $20.4 million during Q4 2022, and its lowest value of $16.5 million during Q3 2025.
- In the last 4 years, Taysha Gene Therapies' Operating Leases had a median value of $18.3 million in 2024 and averaged $18.3 million.
- Per our database at Business Quant, Taysha Gene Therapies' Operating Leases plummeted by 839.97% in 2024 and then plummeted by 701.37% in 2025.
- Taysha Gene Therapies' Operating Leases (Quarter) stood at $20.4 million in 2022, then decreased by 7.27% to $19.0 million in 2023, then fell by 8.4% to $17.4 million in 2024, then dropped by 4.92% to $16.5 million in 2025.
- Its last three reported values are $16.5 million in Q3 2025, $16.8 million for Q2 2025, and $17.1 million during Q1 2025.